沃华医药：预计2025年净利润为8000万元~1.15亿元

Core Viewpoint - Wohuah Pharmaceutical expects a net profit attributable to shareholders of 80 million to 115 million yuan for 2025, representing a year-on-year growth of 119.76% to 215.90% [1] Financial Performance - The basic earnings per share are projected to be between 0.1386 yuan and 0.1992 yuan [1] - The significant increase in profit is attributed to the implementation of refined management practices and the "one reduction and three increases" strategic approach [1] Strategic Initiatives - The company has effectively controlled costs and enhanced academic promotion, focusing on building product academic brands to unlock product potential [1] - Marketing reforms have solidified results, with a more professional and mature sales team adapting to market competition following the entry of Wohuah® Xinkeshu tablets into centralized procurement [1] Market Development - The hospital market has been consolidated and developed, leveraging brand and academic advantages to achieve precise extension and efficient coverage in the outpatient market [1] - A collaborative development model has been established, integrating both hospital and outpatient markets, with outpatient sales beginning to scale [1]